Feb 6 (Reuters) - AstraZeneca AZN.L forecast its 2025 sales above analysts' expectations on Thursday, after the drugmaker's fourth-quarter revenue beat estimates, driven by robust demand, especially for its medicines for cancer and heart diseases.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.